SCHEDULE 13G/A: Tang Capital Divests Entire Stake in Monopar Therapeutics

Sentiment:

Beneficial Ownership Amendment 14 February 2025 9:00 PM

Tang Capital Management and its affiliated entities have reported a 0% beneficial ownership in Monopar Therapeutics Inc., indicating a complete divestment of their previous stake.

Worse than expectedThe reporting entities, Tang Capital Management and its affiliates, have reduced their beneficial ownership in Monopar Therapeutics Inc. to 0%, indicating a complete divestment of their stake. This is generally viewed as a negative signal from a significant institutional investor.

Summary

This document is an Amendment No. 1 to a Schedule 13G filing concerning Monopar Therapeutics Inc.'s Common Stock.
The reporting persons include Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.
As of December 31, 2024, the aggregate amount beneficially owned by these reporting persons in Monopar Therapeutics Inc. is 0 shares, representing 0% of the class of Common Stock.
This filing indicates that the Tang Capital entities have completely divested their beneficial ownership in Monopar Therapeutics Inc.

Sentiment

Score: 3

Explanation: The complete divestment of shares by Tang Capital Management and its affiliates indicates a loss of institutional investor confidence or a strategic exit from the investment, which is a negative signal for the company.

Negatives

The complete divestment of shares by Tang Capital Management and its affiliates could be perceived negatively by the market, suggesting a loss of institutional investor confidence or a strategic exit from the investment.

Future Outlook

Industry Context

This filing reflects a specific change in institutional ownership for Monopar Therapeutics Inc., rather than a broader industry trend. It indicates a significant investor's decision to exit their position in the company.

Stakeholder Impact

Shareholders may view the complete divestment by Tang Capital as a negative signal, potentially impacting investor sentiment and the company's stock price due to the withdrawal of a significant institutional holder.

Key Dates

Date	Description
12/31/2024	Date of event which requires filing of this statement, indicating the reporting persons' beneficial ownership became 0%.
02/14/2025	Filing date of the Schedule 13G Amendment No. 1.

Recommendation

sell

Keywords

Monopar Therapeutics, Tang Capital Management, Schedule 13G, Beneficial Ownership, Stock Divestment, Institutional Investor, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.